Modernizing US regulatory and reimbursement policy to support continued innovation in genomic pathology

ISSN： 1741-0541

Source： Personalized Medicine, Vol.9, Iss.3, 2012-05, pp. : 295-308

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Genomic pathology: a disruptive innovation

By Saffitz Jeffrey E

Personalized Medicine, Vol. 9, Iss. 3, 2012-05 ,pp. : 237-239

Future Medicine

Access to resources Recommend Favorite

Improving Health Care Quality by Reimbursement Policy

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 46, Iss. 6, 1998-06 ,pp. : 788-790

John Wiley & Sons Inc

Access to resources Recommend Favorite

TCORS set to support the FDA's regulatory role: Program designed to generate tobacco‐related research to inform policy

CANCER, Vol. 120, Iss. 6, 2014-03 ,pp. : 771-772

John Wiley & Sons Inc

Access to resources Recommend Favorite

TRIG on TRACK: educating pathology residents in genomic medicine

By Haspel Richard L Atkinson James B Barr Frederic G Kaul Karen L Leonard Debra GB O’Daniel Julianne Rinder Henry M Scott Joan Sobel Mark E Speights VO

Personalized Medicine, Vol. 9, Iss. 3, 2012-05 ,pp. : 287-293

Future Medicine

Access to resources Recommend Favorite

Regulatory Science and the Role of the Regulator in Biomedical Innovation

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 91, Iss. 3, 2012-03 ,pp. : 347-352

John Wiley & Sons Inc

Access to resources Recommend Favorite